Polymer Capital Management HK LTD Buys Shares of 38,665 Biogen Inc. $BIIB

Polymer Capital Management HK LTD bought a new position in Biogen Inc. (NASDAQ:BIIB) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 38,665 shares of the biotechnology company’s stock, valued at approximately $8,354,000.

A number of other hedge funds also recently made changes to their positions in the business. Reflection Asset Management acquired a new position in shares of Biogen during the fourth quarter valued at $25,000. Bell Investment Advisors Inc bought a new position in Biogen in the 2nd quarter valued at about $27,000. WFA of San Diego LLC bought a new position in Biogen in the 2nd quarter valued at about $32,000. Root Financial Partners LLC increased its stake in Biogen by 198.4% during the 4th quarter. Root Financial Partners LLC now owns 185 shares of the biotechnology company’s stock valued at $33,000 after buying an additional 123 shares during the period. Finally, MV Capital Management Inc. bought a new stake in shares of Biogen during the 4th quarter worth about $34,000. Institutional investors own 87.93% of the company’s stock.

Biogen Stock Performance

Shares of NASDAQ BIIB opened at $216.78 on Monday. Biogen Inc. has a one year low of $131.52 and a one year high of $222.15. The firm has a market capitalization of $32.03 billion, a PE ratio of 38.37, a PEG ratio of 6.75 and a beta of 0.17. The company has a current ratio of 1.87, a quick ratio of 1.26 and a debt-to-equity ratio of 0.39. The business has a 50-day moving average price of $205.53 and a two-hundred day moving average price of $194.58.

Biogen (NASDAQ:BIIB) last announced its quarterly earnings data on Wednesday, July 29th. The biotechnology company reported $3.60 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.94 by $0.66. Biogen had a return on equity of 11.18% and a net margin of 8.32%.The business had revenue of $2.74 billion during the quarter, compared to analyst estimates of $2.46 billion. During the same period last year, the company earned $5.47 earnings per share. Biogen’s quarterly revenue was up 3.4% compared to the same quarter last year. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. As a group, analysts predict that Biogen Inc. will post 12.39 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts have recently weighed in on the stock. Bank of America reduced their price target on shares of Biogen from $217.00 to $215.00 and set a “neutral” rating for the company in a research note on Tuesday, July 21st. Weiss Ratings lowered Biogen from a “hold (c)” rating to a “hold (c-)” rating in a research note on Wednesday, August 12th. Guggenheim lifted their price target on Biogen from $260.00 to $280.00 and gave the company a “buy” rating in a research report on Tuesday, July 21st. Royal Bank Of Canada cut their price objective on Biogen from $242.00 to $240.00 and set an “outperform” rating for the company in a report on Thursday, July 30th. Finally, Wolfe Research raised Biogen from a “peer perform” rating to an “outperform” rating and set a $300.00 target price for the company in a research note on Thursday, August 13th. One analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating, thirteen have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $227.07.

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.